Boston has long been a fertile ground for bold ideas and entrepreneurial energy. The city’s unique blend of universities, talent pools, venture capital, and cultural vibrancy makes it one of the strongest ecosystems for scaling companies in the US.
In 2025, a new wave of tech startups closed impressive Series B rounds that not only expanded their reach but also reaffirmed Boston’s global role as a hub for cutting-edge innovation.
This article highlights ten startups headquartered in Boston that raised Series B funding in 2025. The purpose is clear: to showcase how these companies are shaping industries as diverse as AI, biotech, security, and pet health.
Each profile includes the funding raised, core mission, and strategic direction. From digital pet pharmacies to programmable mRNA therapies, these ventures demonstrate how Boston continues to balance science, technology, and creativity.
Linkby – $15M
Linkby secured $15 million in Series B financing led by Volition Capital. This performance PR platform is reinventing how brands collaborate with publishers. Instead of paying upfront for advertorial placements, advertisers only pay when readers engage with the content. 
The model bridges traditional storytelling with modern performance marketing, ensuring that dollars align with measurable results.
The platform already connects more than 600 publishers with brands such as Charlotte Tilbury and Beyond Meat. By focusing on transparency and outcomes, Linkby is carving out a unique space in content-driven marketing campaigns.
The fresh capital will fund U.S. expansion and the launch of new campaign planning tools, reinforcing Boston’s presence in global advertising technology.
The rise of Linkby also signals how marketing technology in Boston continues to thrive in parallel with biotech and AI. In a city best known for research labs and hospitals, a digital advertising startup claiming a strong funding round underlines the depth and diversity of the ecosystem.
Koala Health – $20M
Koala Health raised $20 million in Series B financing with Valspring Capital at the helm. The company has built a mobile-first pharmacy platform that helps pet parents access prescription medications with ease.
By integrating directly with more than 25,000 independent veterinary clinics across all 50 states, Koala makes sure pet owners have seamless access to chronic medications for their animals.
The model solves a longstanding problem: the inconvenience and inconsistency of obtaining pet prescriptions. By leveraging digital tools, Koala enables veterinarians to provide continuity of care without overwhelming their workflows. Pet owners benefit from convenience while practices benefit from streamlined operations.
Boston’s reputation as a health hub extends beyond human medicine. Koala Health proves that innovation in healthcare can reach new corners, extending to veterinary services where convenience, efficiency, and trust are equally important.
VerAI Discoveries – $24M
Boston-based VerAI Discoveries closed a $24 million Series B round led by Insight Partners.
This startup applies AI algorithms to mineral exploration, uncovering high-probability locations of hidden deposits. Mining has traditionally been an industry with significant risks, but VerAI uses technology to bring precision to a process once dominated by guesswork.
The company manages a portfolio of more than 60 mineral projects worldwide, positioning itself as a game-changer for an industry seeking efficiency and environmental responsibility. Its proprietary AI not only speeds up exploration but also reduces wasted investments in unproductive drilling.
With sustainability and responsible sourcing in the spotlight, VerAI represents how Boston’s AI expertise extends far beyond biotech and into industries critical for the global energy transition. By transforming mineral exploration, the company contributes to greener supply chains that support renewable technologies.
Push Security – $30M
Cybersecurity continues to be one of Boston’s strongest verticals. Push Security demonstrated that strength with a $30 million Series B funding round led by Redpoint Ventures. The company focuses on protecting accounts from browser-based attacks such as phishing and credential theft.
Push Security uses lightweight browser agents to monitor employee login activity, detecting threats before they escalate into full breaches.
By concentrating on the “identity perimeter,” the company addresses one of the most common vulnerabilities facing modern enterprises. With Datadog Ventures and B3 Capital also joining the round, Push Security plans to expand its platform and reach new markets.
In an era where digital trust underpins every business, startups like Push Security reinforce Boston’s reputation as a cybersecurity powerhouse. Its success highlights how digital defense continues to evolve with proactive and intelligent solutions.
VideaHealth – $40M
VideaHealth closed a $40 million Series B round to bring artificial intelligence into dental practices. With Spark Capital, Zetta Venture Partners, and Pillar VC among its backers, the company is transforming how dentists detect and diagnose conditions from imaging data.
Its platform already analyzes millions of dental scans, helping practitioners identify issues earlier and with more accuracy.
From pediatric dentistry to complex adult cases, VideaHealth’s solutions improve outcomes while saving time for professionals. By removing ambiguity in diagnosis, the platform empowers dentists to focus on care rather than guesswork.
The investment confirms how Boston’s AI community is addressing specialized areas of healthcare. Dentistry may not always make headlines, yet the opportunity to scale impact through AI illustrates the versatility and depth of Boston’s startup ecosystem.
Maven AGI – $50M
Maven AGI raised $50 million in Series B funding, led by Dell Technologies Capital with Cisco Investments also participating. The company develops enterprise-grade AI agents that automate complex workflows in customer support and operations.
Rather than relying on simple chatbots, Maven AGI orchestrates real-time actions across an enterprise’s systems. By unifying data and processes, its agents deliver consistent and efficient support for clients. The result is improved customer journeys and reduced operational costs.
Boston’s AI scene has often been associated with research labs and academic breakthroughs. Maven AGI demonstrates how those ideas mature into enterprise-ready platforms.
As demand for autonomous AI grows, Maven AGI positions itself at the intersection of scalability and trust, proving that Boston continues to influence the global AI movement.
Imbria Pharmaceuticals – $57.5M
Imbria Pharmaceuticals secured $57.5 million in Series B financing to advance its clinical pipeline for cardiometabolic diseases. The round was led by Deep Track Capital, with participation from Catalio Capital Management and Cytokinetics.
The company’s lead program, ninerafaxstat, targets non-obstructive hypertrophic cardiomyopathy, a heart condition with limited treatment options. With the new funding, Imbria will advance this therapy into Phase 2b trials, offering hope for patients with few alternatives.
Boston’s biotech leadership is undeniable, and Imbria exemplifies that strength. Its combination of scientific rigor, patient focus, and financial backing underscores how deeply the city continues to shape the future of medicine.
Stellaromics – $80M
Stellaromics raised $80 million in a Series B round led by Catalyst4. The company develops Pyxa, a spatial biology platform that provides researchers with unprecedented 3D insights into tissue samples.
By enabling scientists to visualize cells in their native environment with sub-cellular resolution, Stellaromics is reshaping oncology and neuroscience research. Its advanced visualization tools allow for deeper understanding of disease mechanisms, opening pathways to targeted therapies.
The growth of Stellaromics showcases Boston’s dual identity: both a hub of biology and a hub of computation. The convergence of these strengths creates companies that redefine how medicine and research move forward.
Atalanta Therapeutics – $97M
Atalanta Therapeutics secured $97 million in Series B funding led by EQT Life Sciences and Sanofi Ventures. The company develops RNAi therapies that silence genes responsible for neurological diseases.
With programs targeting Huntington’s disease and KCNT1-related epilepsy, Atalanta is preparing for early-stage clinical trials. Its proprietary di-siRNA platform allows therapies to penetrate the central nervous system effectively, addressing diseases that have long lacked viable treatments.
The scale of this round highlights Boston’s dominance in neuroscience innovation. Atalanta exemplifies the city’s ability to bridge world-class science with venture investment, creating hope for patients and long-term impact for society.
Strand Therapeutics – $153M
Strand Therapeutics topped the list with a $153 million Series B round led by Kinnevik. The company engineers programmable mRNA therapies capable of activating only in specific cells and conditions.
This breakthrough approach allows therapies to behave intelligently inside the body, reducing side effects and enhancing precision. With participation from Regeneron Ventures, ICONIQ Growth, and Amgen Ventures, Strand has cemented itself as one of Boston’s most ambitious biotech startups.
By pushing the boundaries of synthetic biology, Strand reflects Boston’s unique edge: the ability to turn advanced academic science into globally relevant medical solutions. Its trajectory reaffirms Boston’s position as the capital of life sciences innovation.
Boston’s Momentum Builds
The 2025 Series B landscape in Boston shows more than just numbers on funding charts. These ten startups are shaping the future of industries as varied as cybersecurity, biotech, AI, and pet health. Together, they embody the resilience, diversity, and ambition that define Boston’s entrepreneurial community.
From Linkby’s performance PR platform to Strand’s programmable mRNA therapies, Boston proves that great ideas can come from any sector and scale globally with the right support. Startups thrive here not only because of capital but also because of the collaborative environment that balances academia, enterprise, and investors.
In short, Boston’s 2025 Series B class shows how innovation grows when science, technology, and capital align. The next wave of growth will not only transform industries but also set benchmarks for collaboration worldwide.
Contact us to learn more about our software development services, and follow us on LinkedIn for more tech trends.
FAQ
Which industries are represented by Boston’s 2025 Series B startups?
The ten highlighted startups span biotech, AI, cybersecurity, advertising technology, mineral exploration, and digital health. This diversity shows Boston’s strength in both science-driven and technology-driven ventures.
Why do Series B rounds matter for these companies?
Series B funding rounds provide capital to scale operations, advance clinical trials, expand platforms, and enter new markets. For Boston startups, these rounds often mark the transition from proving a concept to establishing market leadership.
How does Boston’s ecosystem support this level of funding?
Boston benefits from a strong network of universities, research labs, investors, and entrepreneurs. The city’s collaborative environment enables startups to combine academic insights, corporate expertise, and venture backing in a way that accelerates growth.
Which company raised the largest Series B round in 2025?
Strand Therapeutics secured the largest Series B funding with $153 million. Its programmable mRNA platform attracted global investors eager to back breakthroughs in synthetic biology and advanced therapeutics.
Are these startups limited to the local market?
No. Although headquartered in Boston, many of these startups already operate globally. For example, Koala Health integrates with veterinary clinics across the U.S., while VerAI manages mineral exploration projects around the world.
How do these startups reflect broader innovation trends?
They highlight the convergence of AI, biotech, and digital services. From spatial biology platforms to enterprise AI agents, the startups demonstrate how Boston continues to set benchmarks for how technology evolves across industries.
